← Back to Screener
Genmab A/S ADS (GMAB)
Price$28.30
Favorite Metrics
Price vs S&P 500 (26W)-17.20%
Price vs S&P 500 (4W)1.44%
Market Capitalization$113.30B
P/E Ratio (Annual)18.54x
All Metrics
P/CF (Annual)15.05x
Book Value / Share (Quarterly)$94.89
P/TBV (Annual)4.58x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)21.97%
Cash Flow / Share (Quarterly)$18.35
Price vs S&P 500 (YTD)-11.92%
Gross Margin (TTM)93.60%
Net Profit Margin (TTM)25.89%
EPS (TTM)$15.42
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$15.42
Revenue Growth (5Y)19.19%
EPS (Annual)$15.36
ROI (Annual)8.54%
Gross Margin (Annual)93.60%
Net Profit Margin (5Y Avg)32.29%
Cash / Share (Quarterly)$27.83
P/E Basic Excl Extra (TTM)18.54x
Revenue Growth QoQ (YoY)14.91%
EPS Growth (5Y)6.82%
P/E Normalized (Annual)18.54x
ROA (Last FY)7.48%
Revenue Growth TTM (YoY)19.25%
EBITD / Share (TTM)$17.30
ROE (5Y Avg)17.15%
Operating Margin (TTM)28.63%
Cash Flow / Share (Annual)$18.35
P/B Ratio3.05x
P/B Ratio (Quarterly)3.36x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)5.80x
Net Interest Coverage (TTM)15.44x
ROA (TTM)11.69%
EPS Growth QoQ (YoY)-94.27%
EV / EBITDA (TTM)19.85x
EPS Incl Extra (Annual)$15.36
Current Ratio (Annual)2.02x
Quick Ratio (Quarterly)2.01x
3-Month Avg Trading Volume0.13M
52-Week Price Return-34.04%
EV / Free Cash Flow (Annual)19.06x
P/E Incl Extra (TTM)18.54x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$65.02
P/S Ratio (Annual)4.80x
Asset Turnover (Annual)0.29x
52-Week High$2257.00
Operating Margin (5Y Avg)34.07%
EPS Excl Extra (Annual)$15.36
CapEx CAGR (5Y)3.22%
Tangible BV CAGR (5Y)10.66%
26-Week Price Return-13.21%
Quick Ratio (Annual)2.01x
13-Week Price Return-14.94%
Total Debt / Equity (Annual)0.93x
Current Ratio (Quarterly)2.02x
Enterprise Value$21,560.579
Revenue / Share Growth (5Y)20.38%
Asset Turnover (TTM)0.45x
Book Value / Share Growth (5Y)14.61%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)17.89x
Pretax Margin (Annual)32.37%
Cash / Share (Annual)$27.83
3-Month Return Std Dev38.23%
Gross Margin (5Y Avg)97.53%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)1.70%
EBITDA Interim CAGR (5Y)-22.40%
ROE (Last FY)16.47%
Net Interest Coverage (Annual)3.36x
EPS Basic Excl Extra (Annual)$15.36
P/FCF (TTM)15.78x
Receivables Turnover (TTM)3.67x
EV / Free Cash Flow (TTM)19.06x
Total Debt / Equity (Quarterly)0.93x
EPS Incl Extra (TTM)$15.42
Receivables Turnover (Annual)3.67x
ROI (TTM)13.73%
P/S Ratio (TTM)4.80x
Pretax Margin (5Y Avg)40.72%
Revenue / Share (Annual)$59.34
Tangible BV / Share (Annual)$53.22
Forward P/E24.00x
Free OCF CAGR (5Y)3.84%
Price vs S&P 500 (52W)-44.04%
P/E Ratio (TTM)18.54x
EPS Growth TTM (YoY)-12.17%
Year-to-Date Return-9.27%
5-Day Price Return2.02%
EPS Normalized (Annual)$15.36
ROA (5Y Avg)13.54%
Net Profit Margin (Annual)25.89%
Month-to-Date Return7.36%
Cash Flow / Share (TTM)$32.63
EBITD / Share (Annual)$17.31
EPS Growth (3Y)9.58%
Operating Margin (Annual)28.63%
LT Debt / Equity (Annual)0.86x
P/CF (TTM)15.05x
ROI (5Y Avg)15.25%
P/E Excl Extra (TTM)18.54x
LT Debt / Equity (Quarterly)0.86x
EPS Basic Excl Extra (TTM)$15.42
P/TBV (Quarterly)4.87x
P/B Ratio (Annual)3.36x
Inventory Turnover (TTM)17.89x
Pretax Margin (TTM)32.37%
Book Value / Share (Annual)$94.89
Price vs S&P 500 (13W)-15.63%
Net Margin Growth (5Y)-11.26%
Beta0.59x
P/FCF (Annual)15.78x
Revenue / Share (TTM)$58.94
ROE (TTM)17.35%
52-Week Low$1199.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GMABGenmab A/S ADS | 4.80x | 19.25% | 93.60% | 6.82% | $28.30 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Genmab is a Copenhagen-based biotechnology company developing antibody therapeutics for cancer treatment, leveraging proprietary platforms including DuoBody, HexaBody, and DuoHexaBody. The company has a portfolio of approved products including Darzalex (the standard of care for multiple myeloma), Tepezza, Kesimpta, and others developed through strategic partnerships with major pharmaceutical companies. Genmab maintains a pipeline of candidates targeting additional oncologic indications.